◎ Sugi Atlas

Atlas / Drug / Selumetinib

Selumetinib

drug
On this page

Also known as ARRY-142886ARRY-886Azd-6244AZD6244AZD-6244 HYD-SULFATEAZD-6244 HYDROGEN SULFATESELUMETINIB SULFATEARRAY142886AZD6244 (SELUMETINIB)AZD 6244SELUMETINIB (AZD6244)AZD-6244/ARRY-886SID144206913SID170466898SID174006431

Summary

Selumetinib (CHEMBL1614701) is an approved small-molecule EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor (ATC L01EE04) targeting MAP2K1; indicated across 52 conditions including neoplasm and non-small cell lung carcinoma; with CIViC clinical evidence for 68 variant-indication associations (e.g. NF1 Mutation in plexiform neurofibroma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EE04
  • Targets: 1 (MAP2K1)
  • Indications: 52 conditions
  • Clinical trials: 118
  • Precision-oncology evidence (CIViC): 68 variant–indication associations
  • Chemistry: 457.7 Da · C17H15BrClFN4O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1614701
NameSelumetinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID10127622
ChEBICHEBI:90227
ATCL01EE04
Molecular formulaC17H15BrClFN4O3
Molecular weight457.7
InChIKeyCYOHGALHFOKKQC-UHFFFAOYSA-N

SMILES: CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

IUPAC name: 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

ChEBI definition: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor.

Pharmacological roles (ChEBI): EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, antineoplastic agent, anticoronaviral agent.

Also known as: ARRY-142886, ARRY-886, Azd-6244, AZD-6244, AZD6244, Selumetinib, SELUMETINIB, AZD-6244 HYD-SULFATE, AZD-6244 HYDROGEN SULFATE, SELUMETINIB SULFATE, ARRAY142886, AZD6244 (SELUMETINIB)

Parent form; salt/anhydrous children: CHEMBL2105684

Patent coverage: 3,943 distinct patent families (10,221 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 9,196 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
MAP2K1mitogen-activated protein kinase kinase 1Negative7.924.7%Q02750

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Epidermal growth factor receptor, Dual specificity mitogen-activated protein kinase kinase; MEK1/2, Dual specificity mitogen-activated protein kinase kinase 2, Dual specificity mitogen-activated protein kinase kinase 1, AP2-associated protein kinase 1, Casein kinase II subunit alpha’, Structural maintenance of chromosomes protein 1A, Structural maintenance of chromosomes protein 2, Uncharacterized protein FLJ45252, BMP-2-inducible protein kinase.

Bioactivity

ChEMBL activities: 41 potent at pChembl ≥ 5 of 41 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
MAP2K18.05IC509nMCHEMBL_ACT_18569336
MAP2K17.85IC5014nMCHEMBL_ACT_16423361
MAP2K27.85IC5014nMCHEMBL_ACT_22892123
MAP2K27.85IC5014nMCHEMBL_ACT_24789080
MAP2K17.85IC5014nMCHEMBL_ACT_24953975
MAP2K17.85IC5014nMCHEMBL_ACT_25564480
MAP2K17.85IC5014nMCHEMBL_ACT_29055501
MAP2K17.51IC5031nMCHEMBL_ACT_16423225
MAP2K17.39Kd41nMCHEMBL_ACT_17910382
MAP2K27.28Kd52nMCHEMBL_ACT_17910562
MAP2K17.1IC5080nMCHEMBL_ACT_13294102
MAP2K17Kd99nMCHEMBL_ACT_24954243
MAP2K17Kd99nMCHEMBL_ACT_24957538
MAP2K17Kd99nMCHEMBL_ACT_7569261
SMC26.68Kd209nMCHEMBL_ACT_17939714
SMC1A6.44Kd365nMCHEMBL_ACT_17939561
MAP2K26.28Kd530nMCHEMBL_ACT_24954244
MAP2K26.28Kd530nMCHEMBL_ACT_24957539
MAP2K26.28Kd530nMCHEMBL_ACT_7571046
Q6ZSR96.09Kd807nMCHEMBL_ACT_17933787
AAK15.89Kd1279nMCHEMBL_ACT_17878246
BMP2K5.79Kd1624nMCHEMBL_ACT_17884833
EGFR5.66Kd2200nMCHEMBL_ACT_7569378
CSNK2A25.55Kd2807nMCHEMBL_ACT_17895006
EGFR5.52Kd3000nMCHEMBL_ACT_7569371
MAP2K15.43IC503700nMCHEMBL_ACT_16423360
EGFR5.38Kd4200nMCHEMBL_ACT_7569369
EGFR5.3Kd5000nMCHEMBL_ACT_7569377
EGFR5.28Kd5200nMCHEMBL_ACT_7569370
EGFR5.28Kd5300nMCHEMBL_ACT_7569372

Target pathways

Aggregated over 1 target gene(s): MAP2K1.

Top Reactome pathways

61 total, by targets touching each:

PathwayTargetsGenes
MAPK3 (ERK1) activation1MAP2K1
RAF-independent MAPK1/3 activation1MAP2K1
Developmental Biology1MAP2K1
Cytokine Signaling in Immune system1MAP2K1
Signal Transduction1MAP2K1
Disease1MAP2K1
Toll Like Receptor 4 (TLR4) Cascade1MAP2K1
MyD88:MAL(TIRAP) cascade initiated on plasma membrane1MAP2K1
MyD88-independent TLR4 cascade1MAP2K1
Signaling by NTRKs1MAP2K1
Toll Like Receptor 9 (TLR9) Cascade1MAP2K1
Toll Like Receptor 10 (TLR10) Cascade1MAP2K1
Toll Like Receptor 3 (TLR3) Cascade1MAP2K1
Toll Like Receptor 5 (TLR5) Cascade1MAP2K1
Toll Like Receptor TLR1:TLR2 Cascade1MAP2K1
Toll Like Receptor 7/8 (TLR7/8) Cascade1MAP2K1
Toll Like Receptor TLR6:TLR2 Cascade1MAP2K1
Innate Immune System1MAP2K1
Immune System1MAP2K1
Toll-like Receptor Cascades1MAP2K1
Prolonged ERK activation events1MAP2K1
Frs2-mediated activation1MAP2K1
Toll Like Receptor 2 (TLR2) Cascade1MAP2K1
Signaling by NTRK1 (TRKA)1MAP2K1
Signalling to ERKs1MAP2K1
L1CAM interactions1MAP2K1
Axon guidance1MAP2K1
Signal transduction by L11MAP2K1
Interleukin-1 family signaling1MAP2K1
Interleukin-17 signaling1MAP2K1

Dominant GO biological processes

GO termTargets
MAPK cascade1
regulation of vascular associated smooth muscle contraction1
chemotaxis1
response to oxidative stress1
signal transduction1
heart development1
negative regulation of cell population proliferation1
positive regulation of autophagy1
positive regulation of gene expression1
negative regulation of gene expression1
Schwann cell development1
cerebellar cortex formation1
central nervous system neuron differentiation1
neuron differentiation1
keratinocyte differentiation1

Indications & clinical

Indications

52 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
thyroid gland papillary carcinoma3MONDO:0005075EFO:0000641
thyroid gland carcinoma3MONDO:0015075EFO:0002892
uveal melanoma3MONDO:0006486EFO:1000616
plasma cell myeloma2MONDO:0009693EFO:0001378
cutaneous melanoma2MONDO:0005012EFO:0000389
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
melanoma2MONDO:0005105EFO:0000756
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
adenocarcinoma2MONDO:0004970EFO:0000228
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
gastric adenocarcinoma2MONDO:0005036EFO:0000503
squamous cell carcinoma2MONDO:0005096EFO:0000707
squamous cell lung carcinoma2MONDO:0005097EFO:0000708
colorectal neoplasm2MONDO:0005335EFO:0004142
gallbladder neoplasm2MONDO:0021253EFO:0004606
cholangiocarcinoma2MONDO:0019087EFO:0005221
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
gallbladder carcinoma2MONDO:0003220EFO:1001956
metastatic melanoma2MONDO:0005191EFO:0002617
soft tissue sarcoma2MONDO:0018078EFO:1001968
breast neoplasm2MONDO:0021100MONDO:0007254
lung neoplasm2MONDO:0021117MONDO:0008903
plexiform neurofibroma2MONDO:0003304EFO:0000658
malignant peripheral nerve sheath tumor2MONDO:0017827EFO:0000760
neurofibromatosis type 12MONDO:0018975MONDO:0018975
sarcoma2MONDO:0005089EFO:0000691
tumor of uterus2MONDO:0021353EFO:0003859
bile duct carcinoma2MONDO:0005496EFO:0005540
Kaposi’s sarcoma1MONDO:0005055EFO:0000558
rectal cancer1MONDO:0006519EFO:1000657
chronic myeloid leukemia1MONDO:0011996EFO:0000339
colon carcinoma1MONDO:0002032EFO:1001950
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
optic nerve glioma1MONDO:0003235EFO:0009254
astrocytoma (excluding glioblastoma)1MONDO:0019781MONDO:0016691
colonic neoplasm1MONDO:0005401MONDO:0021063
heart failure1MONDO:0005252EFO:0003144
glioma1MONDO:0021042MONDO:0021637

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 118.

Phase distribution

PhaseTrials
PHASE260
PHASE137
PHASE1/PHASE212
PHASE37
Not specified2

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01933932PHASE3ACTIVE_NOT_RECRUITINGAssess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT03871257PHASE3ACTIVE_NOT_RECRUITINGA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT04166409PHASE3RECRUITINGA Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04576117PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT04924608PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT01843062PHASE3TERMINATEDComparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
NCT01974752PHASE3COMPLETEDSelumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
NCT01089101PHASE1/PHASE2ACTIVE_NOT_RECRUITINGSelumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
NCT01362803PHASE1/PHASE2ACTIVE_NOT_RECRUITINGAZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
NCT02151084PHASE2ACTIVE_NOT_RECRUITINGA Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02299999PHASE2ACTIVE_NOT_RECRUITINGSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT02407405PHASE2ACTIVE_NOT_RECRUITINGMEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT02813135PHASE1/PHASE2RECRUITINGEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT03155620PHASE2ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03392246PHASE2ACTIVE_NOT_RECRUITINGA Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03944772PHASE2ACTIVE_NOT_RECRUITINGPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT05253131PHASE2NOT_YET_RECRUITINGTrial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
NCT05554328PHASE2RECRUITINGTesting the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05564377PHASE2RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT06188741PHASE2RECRUITINGSelumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
NCT06620354PHASE2NOT_YET_RECRUITINGClinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule
NCT06621082PHASE2NOT_YET_RECRUITINGThe Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule
NCT06735820PHASE1/PHASE2NOT_YET_RECRUITINGEarly Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
NCT06763315PHASE2NOT_YET_RECRUITINGLow-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
NCT00338130PHASE2COMPLETEDRandomised Study to Compare the Efficacy of AZD6244 vs TMZ
NCT00372788PHASE2COMPLETEDAZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
NCT00372944PHASE2COMPLETEDAZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
NCT00514761PHASE2COMPLETEDPhase II Efficacy Study of AZD6244 in Colorectal Cancer
NCT00551070PHASE2COMPLETEDSelumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
NCT00553332PHASE2COMPLETEDSelumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
NCT00559949PHASE2COMPLETEDSelumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
NCT00588809PHASE2COMPLETEDSelumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
NCT00604721PHASE2COMPLETEDSelumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00780676PHASE2TERMINATEDPersonalized Treatment Selection for Metastatic Breast Cancer
NCT00866177PHASE2COMPLETEDMEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
NCT00888134PHASE2COMPLETEDSelumetinib in Cancers With BRAF Mutations
NCT00890825PHASE2COMPLETEDAZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
NCT00936221PHASE2COMPLETEDComparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
NCT01011933PHASE2COMPLETEDSelumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01029418PHASE1/PHASE2TERMINATEDAZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Clinical evidence (CIViC)

Variant × indication × effect (68 predictive associations from 73 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
NF1 MutationPlexiform NeurofibromaSensitivity/ResponseSelumetinibCIViC AEID11176 +2
KRAS MutationLung Non-small Cell CarcinomaResistanceSelumetinib + DocetaxelCIViC AEID2998
BRAF V600EHigh Grade GliomaSensitivity/ResponseSelumetinibCIViC BEID2145 +1
KIAA1549::BRAF FusionChildhood Pilocytic AstrocytomaSensitivity/ResponseSelumetinibCIViC BEID7486 +1
BRAF V600EChildhood Pilocytic AstrocytomaSensitivity/ResponseSelumetinibCIViC BEID7485
BRAF V600E OR KIAA1549::BRAF FusionPilocytic AstrocytomaSensitivity/ResponseSelumetinibCIViC BEID11316
BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating MutationCancerSensitivity/ResponseSelumetinibCIViC BEID11696
BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 MutationCancerSensitivity/ResponseSelumetinibCIViC BEID11681
GNA11 Q209Uveal MelanomaSensitivity/ResponseSelumetinibCIViC BEID1212
GNAQ Q209Uveal MelanomaSensitivity/ResponseSelumetinibCIViC BEID1213
KIT RS3733542Acute Myeloid LeukemiaSensitivity/ResponseSelumetinibCIViC BEID1136
KRAS Exon 2 MutationColorectal CancerSensitivity/ResponseSelumetinib + IrinotecanCIViC BEID1326
KRAS G12CLung Non-small Cell CarcinomaSensitivity/ResponseDocetaxel + SelumetinibCIViC BEID1142
KRAS G12VLung Non-small Cell CarcinomaSensitivity/ResponseSelumetinib + DocetaxelCIViC BEID1143
KRAS MutationColorectal CancerSensitivity/ResponseCetuximab + SelumetinibCIViC BEID4866
KRAS MutationLung Non-small Cell CarcinomaSensitivity/ResponseSelumetinib + ErlotinibCIViC BEID4868
KRAS MutationLung Non-small Cell CarcinomaSensitivity/ResponseSelumetinib + DocetaxelCIViC BEID999
NF1 MutationChildhood Low-grade GliomaSensitivity/ResponseSelumetinibCIViC BEID7487
FLT3 ITDAcute Myeloid LeukemiaResistanceSelumetinibCIViC BEID1137
MAP2K1 Q56_V60delOvarian Serous CarcinomaSensitivity/ResponseSelumetinibCIViC CEID1661
NF1 D1644H AND NF1 Q1189*Diffuse AstrocytomaSensitivity/ResponseSelumetinibCIViC CEID12342
NF1 Mutation AND Methylation signature PA-NF1Malignant AstrocytomaSensitivity/ResponseSelumetinibCIViC CEID12270
NF1 Splice Site (c.205-1G>C) AND NF1 G629RPilocytic AstrocytomaSensitivity/ResponseVincristine + Carboplatin + Trametinib + SelumetinibCIViC CEID12271
NRAS Q61Skin MelanomaSensitivity/ResponseSelumetinibCIViC CEID1473
MAP2K1 K57NMelanomaResistanceSelumetinibCIViC CEID7709
BRAF V600EMelanomaSensitivity/ResponseSelumetinibCIViC DEID2129 +1
ATM F858LLung CancerSensitivity/ResponseSelumetinibCIViC DEID5127
BRAF V600EMelanomaSensitivity/ResponseDactolisib + SelumetinibCIViC DEID1005
ERBB3 OverexpressionCancerSensitivity/ResponseSelumetinib + AfatinibCIViC DEID1152
FLT3 ITD OR FLT3 TKD MUTATION OR NRAS EXON 2-3 MUTATION OR PTPN11 Mutation OR KRAS Exon 2-3 MutationAcute Lymphoblastic LeukemiaSensitivity/ResponseSelumetinibCIViC DEID12553

+38 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 12 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

49 molecules share ≥1 primary target. Top 49 by shared-target count:

MoleculeSourceStatusShared targets
BINIMETINIBChEMBL + PubChemPhase 4 (approved)MAP2K1
TRAMETINIBChEMBL + PubChemPhase 4 (approved)MAP2K1
AXITINIBChEMBLPhase 4 (approved)MAP2K1
BOSUTINIBChEMBLPhase 4 (approved)MAP2K1
COBIMETINIBChEMBLPhase 4 (approved)MAP2K1
DASATINIBChEMBLPhase 4 (approved)MAP2K1
FEDRATINIBChEMBLPhase 4 (approved)MAP2K1
GILTERITINIBChEMBLPhase 4 (approved)MAP2K1
NERATINIBChEMBLPhase 4 (approved)MAP2K1
NINTEDANIBChEMBLPhase 4 (approved)MAP2K1
RUXOLITINIBChEMBLPhase 4 (approved)MAP2K1
SORAFENIBChEMBLPhase 4 (approved)MAP2K1
SUNITINIBChEMBLPhase 4 (approved)MAP2K1
TOFACITINIBChEMBLPhase 4 (approved)MAP2K1
VANDETANIBChEMBLPhase 4 (approved)MAP2K1
VEMURAFENIBChEMBLPhase 4 (approved)MAP2K1
AVUTOMETINIBChEMBLPhase 3MAP2K1
CANERTINIBChEMBLPhase 3MAP2K1
DOVITINIBChEMBLPhase 3MAP2K1
LESTAURTINIBChEMBLPhase 3MAP2K1
LINSITINIBChEMBLPhase 3MAP2K1
ORANTINIBChEMBLPhase 3MAP2K1
SARACATINIBChEMBLPhase 3MAP2K1
CENISERTIBChEMBLPhase 2MAP2K1
CEP-32496ChEMBLPhase 2MAP2K1
CI-1040ChEMBLPhase 2MAP2K1
DEFOSBARASERTIBChEMBLPhase 2MAP2K1
E-6201ChEMBLPhase 2MAP2K1
FORETINIBChEMBLPhase 2MAP2K1
ILORASERTIBChEMBLPhase 2MAP2K1
MIRDAMETINIBChEMBLPhase 2MAP2K1
PELITINIBChEMBLPhase 2MAP2K1
PIMASERTIBChEMBLPhase 2MAP2K1
R-406ChEMBLPhase 2MAP2K1
REFAMETINIBChEMBLPhase 2MAP2K1
SOTRASTAURINChEMBLPhase 2MAP2K1
SU-014813ChEMBLPhase 2MAP2K1
TAK-733ChEMBLPhase 2MAP2K1
TOLONIUM CHLORIDEChEMBLPhase 2MAP2K1
TOZASERTIBChEMBLPhase 2MAP2K1
ZAPNOMETINIBChEMBLPhase 2MAP2K1
AfatinibPubChemApprovedMAP2K1
CrizotinibPubChemApprovedMAP2K1
dacomitinibPubChemApprovedMAP2K1
FostamatinibPubChemApprovedMAP2K1
GefitinibPubChemApprovedMAP2K1
IdelalisibPubChemApprovedMAP2K1
PazopanibPubChemApprovedMAP2K1
regorafenibPubChemApprovedMAP2K1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot